Sensorion Provides Update on SENS-401 in Sudden Sensorineural Hearing Loss
MONTPELLIER, FRANCE — Sensorion, a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, today provided an update following supplementary analysis of the 115-patient Phase 2 AUDIBLE-S study of SENS-401 for the treatment of sudden sensorineural hearing loss (SSNHL). As…
Read MoreSensorion Provides Updates on SENS-401 Phase 2 Trial in Sudden Sensorineural Hearing Loss
MONTPELLIER, FRANCE — Sensorion, a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, today reports results from the 115-patient Phase 2 AUDIBLE-S study of SENS-401 (Arazasetron), for the treatment of sudden sensorineural hearing loss (SSNHL). SENS-401 was found to…
Read MoreSensorion Appoints Aniz Girach as Independent Board Member
MONTPELLIER, FRANCE — Sensorion, a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, has announced that Aniz Girach, MD, is joining the Board of directors as an independent Board member. The appointment is effective following the Board meeting, which took place on January…
Read More
Sensorion and Sonova Sign Strategic Research Collaboration
MONTPELLIER, FRANCE — Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN), a pioneering clinical-stage biotech company specializing in the development of novel therapies to restore, treat, and prevent hearing related disorders, and hearing-care industry leader Sonova (SWX:SOON), have signed a multi-year strategic collaboration with the aim of introducing genetic analysis to the routine diagnosis of progressive hearing loss in adults,…
Read More
Sensorion and Cochlear to Begin Trial of SENS-401 for Hearing Preservation in Combination With Cochlear Implantation
MONTPELLIER, FRANCE & SYDNEY, AUSTRALIA — Sensorion, a pioneering clinical-stage biotechnology startup specializing in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, and Cochlear Limited, the global leader in implantable hearing solutions, announce the initiation of a pilot study of the first-in-class small molecule drug SENS-401…
Read MoreSensorion Appoints Gene Therapy and Rare Disease Expert Nora Yang as Chief Scientific Officer
MONTPELLIER, FRANCE — Sensorion, a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, today announces the appointment of Nora Yang, Ph.D., a leader in gene therapy and rare diseases with extensive leadership experience in industry, academia, and government, as…
Read More
Sensorion Presents Promising New Preclinical Data on SENS-401 at ARO 2021
MONTPELLIER, FRANCE – Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces the presentation of three posters at the 2021 Association for Research in Otolaryngology (ARO) Virtual MidWinter Meeting. This includes a poster on the preclinical evidence…
Read More
Sensorion Provides Update on Development of SENS-401 for the Prevention of Hearing Loss
MONTPELLIER, FRANCE — Sensorion, a pioneering clinical stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces it plans to initiate a proof-of-concept clinical trial of SENS-401 to treat cisplatin-induced ototoxicity (CIO) in the second half (H2) of 2021. The company…
Read More
Sonova Acquires 3.7% Stake in Sensorion as the Companies Plan a Collaboration in Hearing Loss
MONTPELLIER, FRANCE — Sensorion, a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces that Sonova Holding AG (headquartered in Switzerland), a leading provider of hearing solutions, will acquire a 3.7% ownership stake in Sensorion by way of subscription…
Read More
Sensorion Reports 2020 First Half Results; Financial Position Strengthened with Recent $36.5M Capital Raise
MONTPELLIER, FRANCE – Sensorion, a pioneering clinical stage and gene therapy biotech company specializing in the development of novel therapies to treat, prevent and restore within the field of hearing loss disorders, announced its interim annual results as of June 30, 2020 alongside its outlook for 2020. “Sensorion’s landmark gene therapy agreement with Institut Pasteur…
Read More